Nadunolimab

Sweden-based Cantargia initiated an expanded Phase I trial of its antibody CAN10, targeting IL-1, IL-33, and IL-36 via IL-1RAP, with no safety concerns reported. The trial aims to assess long-lasting effects, potentially allowing a four-week dosing schedule, focusing on HS and systemic sclerosis. Preclinical models suggest CAN10 reduces disease development in inflammatory conditions. The company plans to advance to Phase II in 2025 and is also developing nadunolimab for oncology.

Cantargia's phase II results for nadunolimab (CAN04) in advanced/metastatic pancreatic cancer (PDAC) published in Clinical Cancer Research. Efficacy better than expected with chemotherapy alone, especially in patients with high IL1RAP levels (median survival 14.2 months). Acceptable safety and reduced neuropathy suggest neuroprotective effect.

Cantargia announced nadunolimab (CAN04) combination therapy results in advanced/metastatic pancreatic cancer, showing better efficacy than chemotherapy alone, with median overall survival of 14.2 months in patients with high IL1RAP tumor levels. The therapy also exhibited a lower-than-expected incidence of neuropathy, suggesting a protective effect.

New data from two clinical trials in 55 patients show nadunolimab's potential in treating patients who have progressed on pembrolizumab, with a median survival of 19.7 months and a disease control rate of 60%. The trials, CANFOUR and CIRIFOUR, highlight nadunolimab's efficacy in targeting immune suppressive cells in the tumor microenvironment.

Cantargia reports strong antitumor effects and encouraging median survival times in nadunolimab combination therapy trials involving 55 cancer patients previously treated with pembrolizumab. The data suggest nadunolimab's unique role in targeting immunosuppressive cells in the tumor microenvironment, with results to be presented at ESMO Congress 2024.